SCHEMBL862333

SCHEMBL862333

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(OC(F)(F)F)ccc2n1Cc1ccc(F)cc1F

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 7/20 0.45
PPARG P37231 2/20 0.40
CYP2C8 P10632 1/20 0.39
SCN9A Q15858 2/20 0.37
SCN5A Q14524 2/20 0.37
ABL1 P00519 1/20 0.37
SERPINE1 P05121 1/20 0.36
KCNK3 O14649 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
CYP2C9 P11712 3/20 0.35
CYP2D6 P10635 2/20 0.35
SCN8A Q9UQD0 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CHRM5 P08912 1/20 0.34
SCN7A Q01118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10257585 0.94 PPARG (0.40) F2RL3PPARGCYP2C8SCN9ASCN5A
SCHEMBL830993 0.92 CYP2C8 (0.39) F2RL3PPARGCYP2C8SCN9ASCN5A
SCHEMBL831730 0.92 PPARG (0.43) F2RL3PPARGCYP2C8KCNK3PTGDR2
SCHEMBL862215 0.92 PPARG (0.43) F2RL3PPARGCYP2C8SCN9ASCN5A
SCHEMBL831825 0.91 CYP2C8 (0.39) F2RL3PPARGCYP2C8SCN9ASCN5A
SCHEMBL10257342 0.90 SERPINE1 (0.43) F2RL3PPARGCYP2C8ABL1SERPINE1
SCHEMBL862485 0.90 PPARG (0.49) F2RL3PPARGCYP2C8SERPINE1CYP2C9
SCHEMBL831566 0.89 PPARG (0.43) PPARGCYP2C8SCN9ASCN5APTGDR2
SCHEMBL862346 0.89 PPARG (0.40) F2RL3PPARGCYP2C8ABL1SERPINE1
SCHEMBL862206 0.89 CYP2C8 (0.43) F2RL3PPARGCYP2C8SCN9ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 F2RL3 1782/4885PPARG 4093/4885CYP2C8 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.